Guoke Junhao, A Developer of Medical Devices and Diagnostic Reagents, completed RMB10 Million in Pre-A Round financing

On April 13, 2019, Guoke Junhao Biotechnology co., LTD (Guoke Junhao) is a Chinese medical device developer and diagnostic reagents. It has completed 10 million RMB in Pre-A round financing with the Guoqian Venture Capital.

Guoke Junhao is a POCT medical device and diagnostic reagent research and development distributor. They are focusing on the field of chemiluminescence immunoassay, mainly developing the small automatic microfluidic immunoassay analyzer, which can achieve inspection automation that is fast, efficient, low cost and simple. The small micro-fluidic chemiluminescence detector developed by the company joins the industry 4.0 technology and combines the concept of remote customer service to achieve an intelligent diagnosis.

Since its establishment, Guoke Junhao has applied for 9 invention patents and 6 utility model patents. With increasing competition at home and abroad, great technology and strong R&D ability will keep the company at the top in this field.

The manager of Guoke Junhao Dr. Lin Jiahui said the company has been researched in disk-type microfluidic chip technology for more than 10 years and has relevant theoretical knowledge, technology, and management ability. "Chemiluminescence, as the most advanced technique in immunodiagnosis, has become the mainstream method of immunodiagnosis in China," she also said.

From the perspective of Guoqian Venture Capital, as a capital firm engaged in equity investment and focused on the field of medical devices, with rich clinical and expert resources, it can accelerate Guoke Junhao’s expansion among the domestic and foreign markets.

Guoqian Venture Capital is an investment platform of Guoqian Medical Technology (Suzhou) co., LTD. The company focuses on the equity investment in the early and middle stage of start-ups in the medical devices business, which is an important step to implement the strategic roadmap of “Industry + Capital”.